Facebook
Google+
https://www.inovotion.com/newsletter-2/newsletter-july-2020">
Twitter
LinkedIn

Newsletter July 2020

WEBINAR: HOW TO OPTIMIZE IN VIVO PRECLINICAL EFFICACY EVALUATION OF SYNERGISTIC IMMUNO-ONCOLOGY DRUG CANDIDATES

Yan WANG, PhD, MD, R&D department, Immuno-Oncology specialist, INOVOTION

During the webinar Dr Yan Wang will discuss:

  • Benefits of setting up an early in vivo efficacy evaluation to optimize probability of success for synergistic Immuno-oncology drug candidate
  • Learn about the chicken embryo model
  • Understand why xenografts on the chicken embryo model are better
  • Use the Chicken embryo in vivo model for early efficacy and toxicity evaluation of Immuno-oncology drug candidates
  • Understand the pros and cons of the chicken embryo model vs mouse model in Immuno-Oncology
  • Case Studies
DOWNLOAD THE VIDEO

Credit: publication authors

NEW PUBLICATION:

INHIBITION OF PATCHED DRUG EFFLUX INCREASES VEMURAFENIB EFFECTIVENESS AGAINST RESISTANT BrafV600E MELANOMA 

Cancers 2020, 12, 1500; doi:10.3390/cancers12061500 

Laurie Signetti, Nelli Elizarov, Méliné Simsir, Agnès Paquet, Dominique Douguet, Fabien Labbal, Delphine Debayle, Audrey Di Giorgio, Valérie Biou, Christophe Girard, Maria Duca, Lionel Bretillon, Corine Bertolotto, Bernard Verrier, Stéphane Azoulay and Isabelle Mus-Veteau

DOWNLOAD THE PUBLICATION

8th Annual PREDiCT TUMOR MODELS - July 14-15 2020

FREE WEBINAR: COMBINATION APPROACH: A BREAKTHROUGH IN VIVO MODEL FOR HIGH-VALUE IDENTIFICATION OF ONCOLOGY CANDIDATES

Wednesday, July 15th: 11:45 AM Boston / 17:45 Europe

Speaker: Dr. Jean Viallet, CEO/CSO at Inovotion 

Come and learn how to explore securing preclinical and clinical results using Inovotion’s model.

  • How to use Inovotion’s technology to open new perspectives for in vivo screening in oncology and immuno-oncology.
  • Why Is the chick embryo model particularly well suited for drug discovery and early identification of high-value compounds in oncology.

This free registration will allow you to attend to all the conferences of the Virtual 8th PREDiCT: Tumor Models Summit (full agenda here)

NEW STANDARDISED CELL LINES

We continuously expand our library of cell lines validated on our model. Our catalog currently includes 50 cell lines and 17 reference compounds

FAQ:

Is the chicken embryo model considered animal testing? Do you need to address ethical regulations to perform studies on the chicken embryo model?

Yes. Using our chicken embryo model, we were successful in obtaining data that correlated well with data obtained from previous mouse studies.

We have tested many types of compounds, from small molecules to antibodies, and have observed excellent correlation with published data in mice.  As with every in vivo model however, the choice of the treatment is an important parameter that must be well discussed and prepared prior to starting a study in ovo

 

FAQ

ABOUT US

Optimizing your preclinical and discovery studies is of prime importance, and INOVOTION has developed a solution based on its unique and cutting-edge in vivo technology.

As a Contract Research Organization (CRO) dedicated to in vivo evaluation for Drug Discovery mainly in oncology, INOVOTION is a sought-after partner for Pharma and Biotech companies as well as academic labs all over the world.

Our main missions are to:

  • Help you find the best candidate anti-cancer treatment
  • Detect the first in vivo toxicity effects of your candidate compounds
  • Improve productivity and Return-On-Investment of your preclinical and Drug Discovery process by maximizing your lead optimization phase

Accelerate the overall Drug Discovery process to answer unmet medical needs in oncology.

Any questions about Inovotion's technology? Contact us at

contact@inovotion.com

INOVOTION SA
HQ & Lab Facilities

+33 475 549 512

5 Avenue du Grand Sablon
38700 La Tronche
France

INOVOTION Inc

185 Alewife Brook Parkway, Suite 210
Cambridge, MA 02138, USA

Facebook
Google+
https://www.inovotion.com/newsletter-2/newsletter-july-2020">
Twitter
LinkedIn

Register for our Newsletter